Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
Myalept, a therapy to treat leptin deficiency is now being sold in the U.S. at a price of $1.9 million after the FDA approved it in 2014.
- Simplified Text
-
Myalept is sold in US for $1.9 million after FDA approval in 2014.
- Confidence Score
- 0.500
- Claim Maker
- Bernie Sanders
- Context Type
- Website Article
- Context Details
-
{ "date": null } - Subject Tags
- UUID
- 9fdb2e75-820c-4ab4-b114-dd9744b9fd3e
- Vector Index
- ✗ No vector
- Created
- September 12, 2025 at 12:34 AM (2 days ago)
- Last Updated
- September 12, 2025 at 12:34 AM (2 days ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
44
claims
🔥
2 days ago
https://www.sanders.senate.gov/op-eds/the-greed-of-big-pharma-cannot-continue/
Senator Sanders criticizes exorbitant prescription drug prices in the US, highlighting the industry's lobbying power and advocating for price controls.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.